Zeliras diabetic nerve pain drug outperforms Lyrica
Filed with ASX · · 6 pages · English
Zelira Therapeutics Ltd. on 6ix
In the deck
Earlier from Zelira Therapeutics
- Trading Halt
- ZLD secures additional US$3.25M investment in HOPE SPV
- March 2023 Quarterly Activities Report
- Zelira raises A$1.77 million from US-based investors
- Appendix 4D & FY23 Interim Financial Report
Later from Zelira Therapeutics
- June 2023 Quarterly Activities Report
- Zelira closes $3.25M funding as part of HOPE SPV fundraise
- September 2023 Quarterly Activities Report
- HOPE SPV receives US$819,000 second tranche of funding
- December 2023 Quarterly Activities Report
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics